Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ: SNY )

53.02 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Where Will Novavax Be in 5 Years?
Its been a good year so far for the biotech, but how long can it keep the momentum going? 
Via The Motley Fool
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... 
Via Benzinga
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets. 
Via InvestorPlace
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns. 
Via InvestorPlace
Sanofi (SNY) Q2 2024 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
Exposures Economy
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. 
Via Benzinga
25 Best Artificial Intelligence Stocks to Buy Right Now
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
Stable Blue-Chip Stocks to Buy Before Earnings Season
Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth. 
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... 
Via Benzinga
Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-stakes pharmaceutical industry deals. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a 
Via Benzinga
3 Stocks to Sell Immediately Based on the French Election Results
Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts. 
Via InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
7 Safe Haven Stocks to Buy Before the Next Market Correction
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. 
Via InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... 
Via Benzinga
Exposures Product Safety
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock. 
Via InvestorPlace
Exposures COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly... 
Via Benzinga
Where Will Novavax Be in 1 Year?
We will know a lot more about the vaccine maker's long-term prospects in 12 months. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.